Related LncRNAs |
ID |
lncRNA Name |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
EL0268 |
CAI2 |
neuroblastoma |
qPCR etc. |
neuroblastoma tissue, cell line (NMB7) |
up-regulated |
N/A |
Concordant expression of CAI2 with p16 and ARF in normal tissue along with the ability of CAI2 to induce p16 expression suggested that CAI2 may regulate p16 and/or ARF. In neuroblastoma cells transformed by serial passage in vitro, leading to more rapid proliferation, CAI2, p16, and ARF expression all increased dramatically. Consistent with its association with high-risk disease, CAI2 expression was also significantly associated with poor clinical outcomes, although this effect was reduced when adjusted for MYCN amplification. |
25028366 |
Lnc2Cancer
|
EL0271 |
CASC15 |
neuroblastoma |
RNA-seq, qPCR, knockdown, Luciferase reporter assay, RNA-FISH etc. |
Neuroblastoma cell lines |
down-regulated |
mutation |
Here we report that the most highly significant single-nucleotide polymorphism (SNP) associations reside within CASC15, a long noncoding RNA that we define as a tumor suppressor at 6p22. Low-level expression of a short CASC15 isoform (CASC15-S) associated highly with advanced neuroblastoma and poor patient survival. |
26100672 |
Lnc2Cancer
|
EL0289 |
CDKN2B-AS1 |
neuroblastoma |
N/A |
N/A |
N/A |
expression |
Disruptions to the expression of ANRIL have accordingly been associated with the development of several cancer types, including neuroblastoma , acute lymphocytic leukaemia, melanoma and prostate |
22817756 |
LncRNADisease
|
EL0556 |
H19 |
neuroblastoma |
N/A |
N/A |
N/A |
regulation |
Epigenetic deregulation of lncRNAs genes is associated with disease |
23791884 |
LncRNADisease
|
EL0558 |
HAGLR |
neuroblastoma |
microarray, qPCR, Northern blot, knockdown etc. |
cell lines (SH-SY5Y) |
up-regulated |
regulation |
One of these lncRNAs, termed HOXD-AS1, is encoded in HOXD cluster. HOXD-AS1 is overexpressed in neuroblastoma. We found that HOXD-AS1 is a subjetc to morphogenic regulation, is activated by PI3K/Akt pathway and itself is involved in control of RA-induced cell differentiation. Knock-down experiments revealed that HOXD-AS1 controls expression levels of clinically significant protein-coding genes involved in angiogenesis and inflammation, the hallmarks of metastatic cancer. |
25522241 |
Lnc2Cancer
|
EL0657 |
LINC00467 |
neuroblastoma |
microarray, qPCR, Luciferase reporter assay, knockdown etc. |
cell lines (BE(2)-C ) |
differential expression |
N/A |
Chromatin immunoprecipitation and luciferase assays showed that N-Myc suppressed linc00467 gene expression through direct binding to the linc00467 gene promoter and reducing linc00467 promoter activity. While N-Myc suppressed the expression of RD3, the protein-coding gene immediately down-stream of linc00467 gene, through direct binding to the RD3 gene promoter and reducing RD3 promoter activity, linc00467 reduced RD3 mRNA expression. Importantly, knocking-down linc00467 expression with siRNA in neuroblastoma cells reduced the number of viable cells and increased the percentage of apoptotic cells, and co-transfection with DKK1 siRNA blocked the effects. |
24586304 |
Lnc2Cancer
|
EL0853 |
MALAT1 |
neuroblastoma |
microarray, qPCR etc. |
cell line (SK-N-SH ) |
down-regulated |
expression |
We identified a shorter transcriptional initiation site and found that CREB binds to the defined proximal promoter of the MALAT1 gene. The expression of the tumor marker MALAT1 ncRNA is sensitive to cell surface receptor activation by oxytocin in a neuroblastoma cell line. |
20149803 |
LncRNADisease Lnc2Cancer
|
EL0853 |
MALAT1 |
neuroblastoma |
microarray, qPCR, knockdown etc. |
cell lines (BE(2)-C, CHP134) |
up-regulated |
N/A |
Here we demonstrated that N-Myc up-regulated the expression of JMJD1A in N-Myc oncogene-amplified human neuroblastoma cells by directly binding to the JMJD1A gene promoter. Affymetrix microarray studies revealed that the gene second most significantly up-regulated by JMJD1A was MALAT1. Consistent with this finding, RT-PCR and chromatin immunoprecipitation assays showed that JMJD1A bound to the MALAT1 gene promoter and demethylated histone H3K9 at the MALAT1 gene promoter. |
24742640 |
Lnc2Cancer
|
EL0861 |
MEG3 |
neuroblastoma |
qPCR etc. |
neuroblastoma tissue |
down-regulated |
epigenetics |
MEG3-DMR is completely methylated in neuroblastoma cell lines. |
15798773 |
LncRNADisease Lnc2Cancer
|
EL0951 |
MYCNOS |
neuroblastoma |
qPCR, Western blot etc. |
neuroblastoma tissue |
up-regulated |
expression |
Both DeltaMYCN and MYCNOS are expressed in all NBs examined. In NBs with MYCN-amplification, these transcripts are significantly higher expressed. the ratio of MYCNOS:MYCN expression is directly correlated with NB disease stage (p = 0.007). In the more advanced NB stages and NBs with MYCN-amplification, relatively more MYCNOS is present as compared to MYCN. Expression of the antisense gene MYCNOS might be relevant to the progression of NB. |
19615087 |
LncRNADisease Lnc2Cancer
|
EL0952 |
MYCNUT |
neuroblastoma |
qPCR, knockdown etc. |
neuroblastoma tissue |
up-regulated |
N/A |
The lncUSMycN gene was coamplified with MYCN in 88 of 341 human neuroblastoma tissues. lncUSMycN RNA bound to the RNA-binding protein NonO, leading to N-Myc RNA upregulation and neuroblastoma cell proliferation. High levels of lncUSMycN and NonO expression in human neuroblastoma tissues independently predicted poor patient prognoses. Treatment with antisense oligonucleotides targeting lncUSMycN in neuroblastoma-bearing mice statistically significantly hindered tumor progression. |
24906397 |
Lnc2Cancer
|
EL0961 |
NBAT1 |
neuroblastoma |
N/A |
N/A |
N/A |
N/A |
The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Loss of NBAT-1 increases cellular proliferation and invasion. |
25517750 |
LncRNADisease
|
EL0972 |
NDM29 |
neuroblastoma |
N/A |
N/A |
N/A |
expression |
In humans, ndm29 maps in a genomic region whose deletion has been shown to be involved in neuroblastoma development. |
16000168 |
|
EL0972 |
NDM29 |
neuroblastoma |
qPCR etc. |
cell lines (NB, NIE-115, SKNBE2 etc.) |
up-regulated |
expression |
The synthesis of a pol III-transcribed noncoding (nc) RNA (NDM29) strongly restricts NB development by promoting cell differentiation, a drop of malignancy processes. NDM29 expression leads to NB cell differentiation. |
20581224 |
LncRNADisease Lnc2Cancer
|
EL1226 |
SNHG16 |
neuroblastoma |
N/A |
N/A |
N/A |
regulation |
It is now becoming increasingly evident that N-myc also regulates the expression of long noncoding RNAs such as T-UCRs and ncRAN. |
22936790 |
LncRNADisease
|
EL1398 |
T-UCRs |
neuroblastoma |
N/A |
N/A |
N/A |
regulation |
It is now becoming increasingly evident that N-myc also regulates the expression of long noncoding RNAs such as T-UCRs and ncRAN. |
22936790 |
LncRNADisease
|
|